CAR therapies
BMS Submits Breyanzi for European Approval as Second-Line Lymphoma Treatment
The CAR T-cell therapy is already approved in Europe as a third-line treatment for relapsed or refractory large B-cell lymphoma.
Mnemo Therapeutics Kicks Off CAR T Clinical Collaboration With €10M Grant
The Paris-based firm will investigate its reprogrammed CAR T-cell therapy in a Phase I/II clinical trial in 35 patients with difficult-to-treat solid tumors.
Eureka, City of Hope Begin Phase I/II Trial of T-Cell Therapy in GPC3-Positive Liver Cancer
The partners will enroll 12 patients with GPC3-positive tumors who have failed or not tolerated at least two prior systemic agents.
Novartis' Kymriah Nabs FDA Approval in Refractory Follicular Lymphoma
The FDA based its decision on data from the ELARA trial, in which 68 percent of patients experienced a complete response to the CAR T-cell therapy.
BMS Shows Breyanzi Benefit in Stem Cell Transplant-Ineligible LBCL
The new data further support the benefit of the CAR T-cell therapy as a second-line option for refractory LBCL patients.Â
May 26, 2022
May 25, 2022
May 19, 2022
Inceptor Bio Raises $37M in Series A Financing
Apr 29, 2022